Literature DB >> 26183790

Independent Assessment of the European Society of Cardiology Sudden Death Risk Model for Hypertrophic Cardiomyopathy.

Barry J Maron1, Susan A Casey2, Raymond H Chan3, Ross F Garberich2, Ethan J Rowin4, Martin S Maron4.   

Abstract

Risk stratification for sudden death (SD) is an essential component of hypertrophic cardiomyopathy (HC) management, given the proven effectiveness of implantable cardioverter-defibrillators (ICD) for preventing SD. Although highly effective in identifying high-risk patients, current stratification algorithms remain incomplete and novel strategies are encouraged. In this regard, reliability of the statistical model to predict SD risk in HC, as recommended by the recent European Society of Cardiology (ESC) guidelines, was retrospectively tested in an independent cohort of 1,629 consecutive patients with HC aged ≥16 years. Of the 1,629 patients, 35 incurred SD events, but only 4 of these (11%) had high predictive risk scores >6%/5 years consistent with an ICD recommendation, and most (60%; n = 21) had scores <4%/5 years that would not justify ICDs. Of 46 high-risk patients with appropriate ICD interventions for ventricular fibrillation/tachycardia, 27 (59%) had low SD risk scores of <4%/5 years, regarded by ESC as insufficient to recommend ICDs, and only 12 (26%) had scores >6%/5 years, considered an ICD indication; 11 of these 12 had already met conventional criteria warranting implantation with 2 to 3 risk markers. Of 414 patients with ICDs but without appropriate interventions, 258 (62%) had low risk scores (<4%/5 years) that would argue against implant. In conclusion, primary risk stratification using the ESC prognostic score applied retrospectively to a large independent HC cohort proved unreliable for prediction of future SD events. Most patients with HC with SD or appropriate ICD interventions were misclassified with low risk scores and therefore would have remained unprotected from arrhythmic SD without ICDs.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26183790     DOI: 10.1016/j.amjcard.2015.05.047

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  39 in total

1.  ESC sudden-death risk model in hypertrophic cardiomyopathy: Incremental value of quantitative contrast-enhanced CMR in intermediate-risk patients.

Authors:  Rocio Hinojar; José Luis Zamorano; Ariana Gonzalez Gómez; Maria Plaza Martin; Amparo Esteban; Luis Miguel Rincón; Juan Carlos Portugal; José Julio Jimenez Nácher; Covadonga Fernández-Golfín
Journal:  Clin Cardiol       Date:  2017-06-14       Impact factor: 2.882

2.  Recommendations of the current guidelines for implantable cardioverter-defibrillator implantation in patients with hypertrophic cardiomyopathy: Debate still exists.

Authors:  Arya Aminorroaya; Ali Vasheghani-Farahani; Farzad Masoudkabir; Pegah Roayaei
Journal:  J Interv Card Electrophysiol       Date:  2020-07-25       Impact factor: 1.900

Review 3.  [Genetic testing to prevent sudden cardiac death].

Authors:  B Stallmeyer; S Dittmann; E Schulze-Bahr
Journal:  Internist (Berl)       Date:  2018-08       Impact factor: 0.743

4.  The relationship between myocardial fibrosis detected by cardiac magnetic resonance and Tp-e interval, 5-year sudden cardiac death risk score in hypertrophic cardiomyopathy patients.

Authors:  Ali Riza Demir; Ömer Celik; Samet Sevinç; Begüm Uygur; Serkan Kahraman; Emre Yilmaz; Mete Cemek; Yilmaz Onal; Mehmet Erturk
Journal:  Ann Noninvasive Electrocardiol       Date:  2019-06-01       Impact factor: 1.468

5.  Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy.

Authors:  Martin S Maron; Ethan J Rowin; Benjamin S Wessler; Paula J Mooney; Amber Fatima; Parth Patel; Benjamin C Koethe; Mikhail Romashko; Mark S Link; Barry J Maron
Journal:  JAMA Cardiol       Date:  2019-07-01       Impact factor: 14.676

Review 6.  Risk stratification in hypertrophic cardiomyopathy.

Authors:  S Marrakchi; I Kammoun; E Bennour; L Laroussi; S Kachboura
Journal:  Herz       Date:  2018-04-25       Impact factor: 1.443

7.  ICD Therapy for Primary Prevention in Hypertrophic Cardiomyopathy.

Authors:  Amar Trivedi; Bradley P Knight
Journal:  Arrhythm Electrophysiol Rev       Date:  2016

Review 8.  Hypertrophic Cardiomyopathy: New Evidence Since the 2011 American Cardiology of Cardiology Foundation and American Heart Association Guideline.

Authors:  Ariane Fraiche; Andrew Wang
Journal:  Curr Cardiol Rep       Date:  2016-07       Impact factor: 2.931

9.  Severe right ventricular hypertrophy in hypertrophic cardiomyopathy: Serious symptoms, complex surgical procedures, and poor prognosis in Fuwai Hospital.

Authors:  Xueqi Dong; Di Zhang; Yi Qu; Xu Meng; Lin Zhao; Xianliang Zhou; Yaxin Liu
Journal:  Anatol J Cardiol       Date:  2021-07       Impact factor: 1.596

10.  Prognostic value of cardiovascular magnetic resonance imaging for life-threatening arrhythmia detected by implantable cardioverter-defibrillator in Japanese patients with hypertrophic cardiomyopathy.

Authors:  Yasuki Hen; Mayuko Tsugu-Yagawa; Nobuo Iguchi; Yuko Utanohara; Kaori Takada; Haruhiko Machida; Ayako Takara; Kunihiko Teraoka; Kanki Inoue; Itaru Takamisawa; Morimasa Takayama; Tsutomu Yoshikawa
Journal:  Heart Vessels       Date:  2017-08-01       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.